Search clinical trials for: PF-03893787

Total 1303 results

Pfizer

Completed

Clinical Trial In Healthy Volunteers And Health Elderly Volunteers To Evaluate The Safety, Tolerability And Blood Concentration After Single And Multiple Escalating Oral Doses Of PF-06751979.

Healthy Subjects

Belgium
Pfizer

Recruiting

A Study to Learn About the Study Medicine (Called Lorlatinib) in People With Liver Dysfunction

Healthy Volunteers | Moderate Hepatic Impairment | Severe Hepatic Impairment

United States
Pfizer

Completed

A Study to Learn About the Study Medicine PF-07853578 and How it Acts in the Bodies of Healthy Adults

Healthy Participants

United States
Teva Branded Pharmaceutical Products R&D, Inc.

Completed

A Study to Evaluate the Efficacy and Safety of Fremanezumab for Preventive Treatment of Migraine in Patients With Major Depressive Disorder

Migraine | Major Depressive Disorder

United States, Czechia, Finland, Israel, Italy, Russian Federation, Spain, Ukraine, France, Germany, Greece, Poland, United Kingdom
Pfizer

Completed

Effect Of Hepatic Impairment on the Pharmacokinetics, Safety and Tolerability of PF-06865571 In Subjects With Hepatic Impairment and in Healthy Subjects

Healthy Volunteers | Hepatic Impairment

United States
Pfizer

Completed

Evaluation Of The Efficacy And Safety Of Single Doses Of PF-05089771 In Patients With Primary (Inherited) Erythromelalgia (IEM)

Inherited Erythromelalgia

United States
Duke University
Pfizer

Completed

Safety Study of Regorafenib With PF-03446962 to Treat Colorectal Cancer (REGAL-1)

Colorectal Cancer

United States
Pfizer

Completed

Study To Evaluate Safety And Tolerability Of Single And Multiple Ascending Doses Of PF- 06260414 In Healthy Western And Japanese Male Subjects

Healthy

United States
Molecular NeuroImaging

Completed

Phase 0 Study of [18F]MNI-968 as a Marker for D1 Receptor in Healthy Subjects

Healthy Volunteers

United States
Pfizer

Completed

Evaluation Of Safety, Tolerability And Pharmacokinetics Of Single And Multiple Doses Of Compound PF-06823859

Healthy

United States
Pfizer

Completed

A 12-week Study To Evaluate PF-06291874 Once a Day in Adults With T2DM Inadequately Controlled On Metformin

Type 2 Diabetes Mellitus

United States, Canada
Pfizer

Completed

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of PF-06649751 in Parkinson's Disease

Parkinson's Disease

United States, Belgium
Pfizer

Terminated

A 6-Week Study To Determine The Safety And Effect Of An Investigational Drug Given With Canagliflozin In Adults With Type 2 Diabetes Mellitus Taking Metformin

Type 2 Diabetes Mellitus

United States
Pfizer

Completed

A Multiple Dose Study Of PF-06678552 In Healthy Subjects

Healthy

Belgium
Pfizer

Terminated

A Study to Evaluate the Safety, Tolerability, and Blood Levels of PF-03654746 in Subjects With Mild to Moderate Alzheimer's Disease

Alzheimer's Disease

United States
Pfizer

Withdrawn

A Study Of The Safety, Tolerability, And Pharmacokinetics Of Multiple Doses Of PF-05180999 In Healthy Adults

Migraine
Pfizer

Completed

A Multiple Dose Study Of PF-04620110 In Type 2 Diabetes Patients

Type 2 Diabetes Patients

United States
Pfizer

Completed

Effect of PF-04360365 On ABETA In Patients With Alzheimer's Disease And Healthy Volunteers

Alzheimer's Disease

United States, Sweden
Pfizer

Completed

Safety And Pharmacokinetics Study Of PF-04287881 In Healthy Adults

Respiratory Tract Infections

United States
Pfizer

Completed

A Phase 1 Single-Dose Escalation Study of PF-04308515 in Healthy Volunteers

Healthy Volunteers

United States
Pfizer

Recruiting

A Study to Learn About the Study Medicine Called PF-07799933 in People With Advanced Solid Tumors With BRAF Alterations.

Glioma | Melanoma | Thyroid Cancer | Non-Small-Cell Lung Cancer

United States, Canada, Israel
ECOG-ACRIN Cancer Research Group
National Cancer Institute (NCI)

Recruiting

Crizotinib in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Removed by Surgery and ALK Fusion Mutations (An ALCHEMIST Treatment Trial)

Stage IB Non-Small Cell Lung Carcinoma AJCC v7 | Stage II Non-Small Cell Lung Cancer AJCC v7 | Stage IIA Non-Small Cell Lung Carcinoma AJCC v7 | Stage IIB Non-Small Cell Lung Carcinoma AJCC v7 | Stage IIIA Non-Small Cell Lung Cancer AJCC v7 | ALK Gene Rearrangement | ALK Gene Translocation | ALK...

United States, Guam, Puerto Rico
Pfizer

Completed

Study to Evaluate Efficacy and Safety of PF-04965842 in Subjects Aged 12 Years And Older With Moderate to Severe Atopic Dermatitis (JADE Mono-1)

Dermatitis, Atopic

United States, Hungary, Canada, Germany, Australia, Czechia, Poland, United Kingdom
Pfizer

Completed

Evaluation of Skin Irritation Potential With PF-06700841 Cream Formulation Using Negative Control in Adult Japanese Healthy Participants

Healthy

Japan
Pfizer

Active, not recruiting

A Study of Recombinant AAV2/6 Human Factor 8 Gene Therapy SB-525 (PF-07055480) in Subjects With Severe Hemophilia A

Hemophilia A

United States
Pfizer

Completed

A Study to Learn About Lorlatinib in Patients With Non-Small Cell Lung Cancer Which Could Not Be Controlled

Non-Small Cell Lung Carcinoma

Taiwan
Pfizer

Completed

A Study of Single Ascending Doses of PF-07258669 in Healthy Adult Participants

Healthy Participants

United States
SIFI SpA

Completed

Clinical Investigation on the Use of Ophthalmic Solution Based on Sodium Hyaluronate in Treatment of Eye Discomfort

Ocular Dryness

Italy
Pierre Fabre Medicament

Completed

Phase 1 Safety Study of Encorafenib in Chinese Patients With Advanced Metastatic BRAF V600E Mutant Solid Tumors (OCEANI)

Melanoma | BRAF V600E Unresectable or Metastatic Melanoma | BRAF V600E Metastatic NSCLC

China
Biogen

Completed

Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Repeated Doses of PF-04958242 in Healthy Volunteers

Schizophrenia

United States
Biogen

Completed

A Study Of The Effects Of PF-04958242 In Subjects With Age-Related Hearing Loss

Hearing Loss, Sensorineural

United States
Biogen

Completed

A Study To Examine The Safety, Tolerability And Pharmacokinetics Of PF-04958242 In Psychiatrically Stable Subjects With Schizophrenia

Schizophrenia

United States
Pfizer

Completed

A Study To Examine The Safety, Tolerability And Pharmacokinetics Of PF-02545920 In Psychiatrically Stable Subjects With Schizophrenia

Schizophrenia

United States
Pfizer

Completed

First In Human, Single Escalating Oral Dose Study Of PF-06882961 In Healthy Adult Subjects

Healthy Subjects

United States
Pfizer

Terminated

An Outpatient Study Of The Efficacy, Safety, And Tolerability Of PF-02545920 In The Adjunctive Treatment Of Sub-Optimally Controlled Symptoms of Schizophrenia

Schizophrenia

United States
Pfizer

Terminated

A 6-Week Study To Determine The Safety And Effect Of An Investigational Drug On Adults With Type 2 Diabetes Mellitus Taking Metformin

Type 2 Diabetes Mellitus

United States
Pfizer

Completed

A Multiple Oral Doses Study Of PF-06427878 In Healthy Adult Subjects

Healthy Subjects

Belgium
Pfizer

Completed

Study to Evaluate Safety and Tolerability of Single Ascending Doses of Multiple Formulations of PF-06650833 in Healthy Subjects Under Fasted and Fed Conditions

Healthy

United States
Pfizer

Completed

Study to Investigate the Safety, Tolerability, Pharmacokinetics of PF-06305591 in Healthy Male and Female Subjects

Healthy

Belgium
Pfizer

Terminated

Study to Test the Safety and Tolerability of PF-07209960 in Advanced or Metastatic Solid Tumors

Renal Cell Carcinoma | Non-small-cell Lung Cancer | Squamous Cell Carcinoma of the Head and Neck | Urothelial Carcinoma | Colorectal Carcinoma | Ovarian Carcinoma

United States
Pfizer

Completed

A Target Occupancy Study With Ritlecitinib.

Healthy

United States
Telavant, Inc.
Pfizer

Completed

Evaluation of Safety, Tolerability and Pharmacokinetics of Single Dose of PF-06480605 in Japanese Healthy Participants

Healthy

Japan
H. Lee Moffitt Cancer Center and Research Institute
Pfizer

Completed

Phase II Hedgehog Inhibitor for Myelodysplastic Syndrome (MDS)

Chronic Myelomonocytic Leukemia (CMML) | Myelodysplastic Syndrome (MDS)

United States
Pfizer

Completed

Trial Of PF-00299804 In Patients With Advanced Refractory Lung Cancer

Carcinoma, Non Small Cell Lung

Korea, Republic of
Pfizer
Yale University

Completed

A Phase I, Healthy Volunteer Positron Emission Tomography Study

Healthy

United States
Ronald Levy
Pfizer

Completed

A Phase 2 Intratumoral Injection PF-3512676 Plus Local Radiation in Low-Grade B-Cell Lymphomas

Lymphoma | Lymphoma, Non-Hodgkin | Lymphomas: Non-Hodgkin | Lymphomas: Non-Hodgkin Follicular / Indolent B-Cell

United States
Pfizer

Completed

Bioavailability Study Of PF-06651600 In Healthy Subjects

Healthy

Belgium
Pfizer

Completed

A Study To Assess The Efficacy And Safety Of PF-04236921 In Subjects With Crohn's Disease Who Failed Anti-TNF Therapy (ANDANTE)

Crohn's Disease

United States, Denmark, Ireland, Australia, Belgium, Israel, Italy, Canada, Czech Republic, Hungary, Germany, United Kingdom, Brazil, New Zealand, France, Greece, Switzerland, Romania
Pfizer

Completed

A Phase I Trial to Investigate the Safety and Tolerability of PF-06649751

Healthy

United States
Pfizer
Yale University

Completed

Evaluation Of Striatal Glucose Metabolism With Positron Emission Tomography Following PF-02545920 In Healthy Subjects

Healthy

United States

3

Subscribe